Effect of Peri-operative Glucocorticoids on Short-term Functional Outcome After THA

Patients listed for a direct anterior total hip arthroplasty by a single surgeon will be recruited for this study and allocated to one of two groups:

• intervention group: 25 grams of iv dexamethasone at induction followed by 10 mg of iv dexamethasone 12 hours later
• control group: 5 grams of iv dexamethasone at induction followed by placebo 12 hours later Both patients and surgeons will be blinded. Primary outcome measure will be number of steps during the first 6 weeks as measured by a pedometer. Secondary outcome measures will be side effects, complications, Patient Reported Outcome Measures, pain, nausea, stiffness, achievement of clinical milestones and use of analgesia/anti-emetics. This data will be collected using a tailor made application for a smartphone or tablet and data collecting will start one week before surgery until 6 weeks after surgery.

Based on a power analysis both groups will consist of 35 patients each.

Inclusion criteria

• All patients undergoing unilateral uncemented THA for primary OA or AVN of the hip under general anesthesia (GA)
• Aged 18 years and above (including women of child bearing age)
• Able to provide informed consent

Exclusion criteria

• Younger than 18 years
• Known alcohol or drug abuse
• Known allergy for glucocorticoids
• Administration of any glucocorticoids in the last three months
• Usage of strong analgesia (such as lyrica or oxycodone) as regular medication
• Usage of medication with anticipated interactions with glucocorticoids
• Known gastric ulcer
• Insulin dependent diabetes mellitus
• Severe heart disease (NYHA > 2)
• Liver or renal failure
• Systemic rheumatoid diseases
• Insufficient understanding of the Dutch language
• Unable to provide informed consent
• Pre-operative use of walking aids
• Gross anatomical deformities
• Significant intra-operative complications such as periprosthetic fracture